Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

IMV Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Post by europe10on Jan 09, 2023 8:45am
370 Views
Post# 35210637

update a Sunday?

update a Sunday?Strange,
Update on a Sunday
The inevitable very dilutive financing came in even worse than I feared
Half of the company given away
Any advantages? Only if Wainwright decides to take it for a run. 65 $ target.....
Market now "know " that Feb test results will be good for the DLBCL trial.
To be released in Feb. But will cost money to test in phase 3, that IMV does not have. Deal?
There has been some crazy runs in the sector lately
So maybe.....

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities